 InspireMD, Inc. NYSE American: NSPR, the developer of the CGuardTM Embolic Prevention System EPS for the prevention of stroke caused by carotid artery disease, announced today the closing, on June 5, 2020, of its 11.5 million follow-on underwritten public offering, which included 1.5 million from the exercise, in full, by the underwriter of its over-allotment option for the offering. Pursuant to the offering, InspireMD issued 25,555,500 shares of common stock or common stock equivalents, along with an equivalent number of Series F warrants to purchase common stock, in units, at a price to the public of 0.45 per unit. Each Series F warrant is exercisable for one share of common stock at an exercise price of 0.495 per share. 